69383-71-7

Basic information

• Product Name: Benzoic acid, 3-[(dimethylamino)carbonyl]-, methyl ester
• CAS NO: 69383-71-7
• Molecular Formula: C11H13NO3
• Molecular Weight: 207.229
• Mol File: 69383-71-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-[(dimethylamino)carbonyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-[(dimethylamino)carbonyl]-, methyl ester(69383-71-7)
• EPA Substance Registry System: Benzoic acid, 3-[(dimethylamino)carbonyl]-, methyl ester(69383-71-7)

Safety Data

• Hazardous Substances Data: 69383-71-7(Hazardous Substances Data)

Upstream product

• 1877-71-0 benzene 1,3-dicarboxylic acid monomethyl ester 
• 3441-03-0 3-(methoxycarbonyl)benzoyl chloride 
• 124-40-3 dimethyl amine 
• 68-12-2 N,N-dimethyl-formamide 
• 1459-93-4 dimethyl Isophthalate 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 283608-49-1 3-Hydroxymethyl-N,N-dimethylbenzamide 
• 858981-15-4 3-(dimethylcarbamoyl)benzoic acid 
• 69384-56-1 C₁₅H₂₄N₄O₂S 
• 69384-52-7 C₁₅H₂₃N₅S 
• 69384-24-3 2-[[3-(N,N-Dimethylaminomethyl)phenyl]methylthio]ethanamine 
• 69383-72-8 3-(N,N-Dimethylaminomethyl)benzenemethanol 

Relevant articles and documents

Structure–Activity Relationships of 1-Benzoylazulenes at the OX1 and OX2 Orexin Receptors

We previously demonstrated the potential of di- or trisubstituted azulenes as ligands (potentiators, weak agonists, and antagonists) of the orexin receptors. In this study we investigated 27 1-benzoylazulene derivatives, uncovering seven potentiators of t

A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N -[3-[(Benzimidazol-2-yl)amino]propyl]amides

Malaria continues to be a major global health problem, being particularly devastating in the African population under the age of five. Artemisinin-based combination therapies (ACTs) are the first-line treatment recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance against them has already been reported. As a consequence, novel chemotypes are urgently needed. Herein we report a novel, in vivo active, fast-acting antimalarial chemotype based on a benzimidazole core. This discovery is the result of a medicinal chemistry plan focused on improving the developability profile of an antichlamydial chemical class previously reported by our group. (Graph Presented).

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.